{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:32Z","timestamp":1778274452759,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1053\/j.ajkd.2014.01.015","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T13:46:28Z","timestamp":1392385588000},"page":"1022-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Thrombotic Microangiopathy and Acute Kidney Injury Associated With Intravenous Abuse of an Oral Extended-Release Formulation of Oxymorphone Hydrochloride: Kidney Biopsy Findings and Report of 3 Cases"],"prefix":"10.1053","volume":"63","author":[{"given":"Josephine M.","family":"Ambruzs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Serrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeem","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2014.01.015_bib1","first-page":"324","article-title":"Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain","volume":"35","author":"Craig","year":"2010","journal-title":"PT"},{"key":"10.1053\/j.ajkd.2014.01.015_bib2","unstructured":"Endo Pharmaceuticals announces reformulated version of Opana ER with INTAC technology designed to be crush-resistant accounts for more than 90 percent of Opana ER total prescription volume. PR Newswire. September 6, 2012. http:\/\/www.prnewswire.com\/news-releases\/endo-pharmaceuticals-announces-reformulated-version-of-opana-er-with-intac-technology-designed-to-be-crush-resistant-accounts-for-more-than-90-percent-of-opana-er-total-prescription-volume-168750546.html. Accessed July 31,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.015_bib3","first-page":"1","article-title":"Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse\u2014Tennessee, 2012","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.ajkd.2014.01.015_bib4","unstructured":"US Food and Drug Administration (FDA). FDA warns about\u00a0serious blood disorder resulting from misuse of Opana ER. October 11, 2012, and November 1, 2012. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm322432.htm. Accessed August 8,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.015_bib5","unstructured":"Centers for Disease Control and Prevention (CDC). Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER. Health Alert Network (HAN). October 26, 2012. http:\/\/www.bt.cdc.gov\/han\/han00331.asp. Accessed August 8,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.015_bib6","unstructured":"Innovative formulation technology: protecting intended drug\u00a0action. INTAC by Gr\u00fcnenthal. Gr\u00fcnenthal Innovation. http:\/\/www.grunenthal.com\/cms\/cda\/_common\/inc\/display_file.jsp?fileID=215700010. Accessed July 31,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.015_bib7","unstructured":"US Food and Drug Administration (FDA). FDA statement: original Opana ER relisting determination. May 10, 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm351357.htm. Accessed July 31,\u00a02013."},{"key":"10.1053\/j.ajkd.2014.01.015_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5858\/135.2.249","article-title":"The Movat pentachrome stain as a means of identifying microcrystalline cellulose among other particulates found in lung tissue","volume":"135","author":"Sigdel","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.ajkd.2014.01.015_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jat\/33.9.615","article-title":"Oxymorphone-involved fatalities: a report of two cases","volume":"33","author":"McIntyre","year":"2009","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1053\/j.ajkd.2014.01.015_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jat\/34.2.78","article-title":"Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine","volume":"34","author":"Gingras","year":"2010","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1053\/j.ajkd.2014.01.015_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:22:31Z","timestamp":1759458151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0272638614000900"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.015","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy and Acute Kidney Injury Associated With Intravenous Abuse of an Oral Extended-Release Formulation of Oxymorphone Hydrochloride: Kidney Biopsy Findings and Report of 3 Cases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}